You're asking about **10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide**, which is a chemical compound and not a known biological entity.
It's likely you're referring to a **similar compound**, possibly:
* **10,11-dihydro-10,11-dihydroxy-5H-dibenzo[b,f]azepine-5-carboxamide**, also known as **5-carboxamido-10,11-dihydro-10,11-dihydroxy-dibenzo[b,f]azepine** (CAS number: 64874-25-8). This compound is actually a **precursor** to the important **antidepressant drug, imipramine**.
**Here's why this compound is important in research:**
* **Drug Development:** The precursor serves as a crucial intermediate in the synthesis of imipramine. Understanding its chemistry and reactivity is essential for developing efficient and safe methods for imipramine production.
* **Medicinal Chemistry:** Studying this compound and its derivatives can provide insights into the structure-activity relationship of tricyclic antidepressants like imipramine. This knowledge could help design new and improved antidepressants with fewer side effects and greater efficacy.
* **Pharmacological Research:** Investigating the pharmacological properties of this compound and its potential therapeutic applications in other areas, such as pain management or neuroprotection, may be valuable.
**Important Note:** Without knowing the exact compound you're interested in, it's difficult to provide specific details. However, the information above should give you a good starting point for your research.
**To get more specific information, you'll need to:**
1. **Double-check the chemical name and CAS number**.
2. **Consult reliable databases like PubChem or ChemSpider**.
3. **Look for relevant scientific publications on the compound**.
Let me know if you have any other questions.
10,11-dihydro-10,11-dihydroxy-5H-dibenzazepine-5-carboxamide: metabolite of carbamazepine; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 83852 |
| CHEBI ID | 4592 |
| SCHEMBL ID | 14317737 |
| MeSH ID | M0046028 |
| Synonym |
|---|
| 10,11-dihydro-10,11-dihydroxy-5h-dibenzazepine-5-carboxamide |
| C07495 |
| 10,11-dihydroxycarbamazepine |
| dihydroxycarbazepine |
| 35079-97-1 |
| cgp 10,000 |
| 10,11-dihydro-10,11-dihydroxycarbamazepine |
| carbamazepine-10,11-diol |
| cbzd |
| carbazepine 10,11-diol |
| cbz-diol |
| 10,11-dihydroxy-10,11-dihydrocarbamazepine |
| FT-0666958 |
| 5,6-dihydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide |
| 5h-dibenz(b,f)azepine-5-carboxamide, 10,11-dihydro-10,11-dihydroxy- |
| carbamazepine-10,11-dihydrodiol |
| SCHEMBL14317737 |
| CHEBI:4592 |
| PRGQOPPDPVELEG-UHFFFAOYSA-N |
| 10,11-dihydroxy-10,11-dihydro-5h-dibenzo[b,f]azepine-5-carboxamide # |
| DTXSID30891504 |
| Q27106416 |
| PD165959 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Some other pharmacokinetic aspects which could be useful in extrapolating to the amount and time of ingestion of the overdose are discussed." | ( Pharmacokinetic aspects of carbamazepine and its two major metabolites in plasma during overdosage. Aucamp, AK; Hundt, HK; Müller, FO, 1983) | 0.27 |
| " The apparent elimination half-life of the monohydroxy-metabolite [19 (SD 3) h] in these patients was about twice that in healthy subjects." | ( The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Aldigier, JC; Darragon, T; Godbillon, J; Hillion, D; Jungers, P; Kourilsky, O; Lecaillon, JB; Menard, F; Meyer, P; Rouan, MC, 1994) | 0.29 |
| " A linear pharmacokinetic model which describes clearances of parent and metabolite is developed." | ( A partial area difference analysis for estimating elimination rate constants and distribution volumes of metabolites. Riad, LE; Sawchuk, RJ, 1998) | 0.3 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "min-1), the glucuronides of oxcarbazepine and its monohydroxy-metabolite are likely to accumulate during repeated administration, and dosage adjustment of oxcarbazepine in these patients could not be proposed from this single administration study." | ( The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Aldigier, JC; Darragon, T; Godbillon, J; Hillion, D; Jungers, P; Kourilsky, O; Lecaillon, JB; Menard, F; Meyer, P; Rouan, MC, 1994) | 0.29 |
| " Sectional hair analysis of a patient on a constant dosage of CBZ demonstrates an exponential decrease in hair concentrations of CBZ and CBZ-diol with increasing distance from the root, probably caused by shampooing." | ( High-performance liquid chromatographic determination of carbamazepine and metabolites in human hair. Brekelmans, GJ; Edelbroek, PM; Rademaker, RV; Saris, LA; van der Linden, GJ, 1997) | 0.3 |
| Class | Description |
|---|---|
| dibenzoazepine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (28.57) | 18.7374 |
| 1990's | 23 (54.76) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 2 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.34) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (18.75%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (4.17%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 37 (77.08%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||